Skip to content

Turning Biological Complexity into R&D Advantage with Virtual Cells - with Giorgio Gaglia of Sanofi & Daniel Veres of Turbine

October 5, 2026 · 32 min

Show notes

Drug discovery teams are running short of new ideas to test, and AI models that simulate how cells respond to drugs only pay off once leaders know when those predictions can be trusted with experiments, timelines, and budget. In this episode, Daniel Veres, Co-Founder and Chief Scientific Officer at Turbine, and Giorgio Gaglia, Head of Systems and Disease Biology at Sanofi, examine with host Yolandi de Weerdt how testing models on data they have never seen shows which R&D decisions their predictions can reliably inform. The discussion offers R&D leaders a practical way to judge when a model's predictions are ready to inform which experiments to run, where in the pipeline to start, and how much risk to accept. This episode is sponsored by Turbine. Learn how these conversations drive pipeline for other AI brands — download our media kit at emerj.com/AD1

All episodes of The AI in Business Podcast

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.